News

The latest in features and updates that are relevant to sickle cell research, from publications around the world.

Sickle Cell Warrior Program from NMDP/Be The Match Helps Eliminate Barriers to Equitable Care

20 Sep 2022

The free program helps individuals become more care-prepared through information, resources, connections, counseling and support.

Learn more

Patients With Sickle Cell Disease Less Likely to Receive Specialized Care

16 Sep 2022

A recent analysis of Medicaid claims data found that individuals with sickle cell disease are seeing hematologists at a lower rate than patients with other chronic genetic diseases.

Learn more

With rare acquisition, Novo Nordisk makes $1B bet on sickle cell disease drug

07 Sep 2022

Danish drugmaker Novo Nordisk will spend $1.1 billion to acquire Forma Therapeutics, a 15-year-old biotechnology company that formed to discover cancer medicines but now has an experimental drug in late-stage testing for treating sickle cell disease.

Learn more

A Proclamation on National Sickle Cell Awareness Month, 2022

31 Aug 2022

President of the United States of America, by virtue of the authority vested in him by the Constitution and the laws of the United States, proclaimed September 2022 as National Sickle Cell Awareness Month.

Learn more

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

23 Aug 2022

Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat population

Learn more

African health ministers launch drive to curb sickle cell disease toll

23 Aug 2022

African health ministers today launched a campaign to ramp up awareness, bolster prevention and care to curb the toll of sickle cell disease, one of the most common illnesses in the region but which receives inadequate attention.

Learn more

Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

11 Aug 2022

First patient has been dosed with GPH101, now called nulabeglogene autogedtemcel (nula-cel), in the company’s Phase 1/2 CEDAR trial in people with sickle cell disease (SCD). Nula-cel is an investigational gene editing therapy designed to directly correct the genetic mutation that causes SCD and definitively cure the disease.

Learn more

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

08 Aug 2022

Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD).

Learn more

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

16 Jul 2022

Gene editing of HSCs in vivo via a non-viral delivery system offers the potential to transform the treatment of sickle cell disease (SCD) and other inherited blood disorders by overcoming the complexity and safety risks of ex vivo approaches.

Learn more

Inhaled nitric oxide for treating pain crises in people with sickle cell disease

08 Jul 2022

Can inhaled nitric oxide relieve pain crises in people with sickle cell disease and does it have other beneficial effects (such as lessening the severity of pain?)

Learn more

Researchers have found that new sickle cell disease gene therapies depend on choosing the right laboratory mice.

07 Jul 2022

Scientists from St. Jude Children’s Research Hospital, US, have been investigating a promising new sickle cell treatment by editing genes to switch on the production of healthy, fetal hemoglobin in adult red blood cells.

Learn more

Evidence Unclear About Superiority of Exchange Transfusion Types in Sickle Cell Disease

10 Jun 2022

For patients with sickle cell disease (SCD), exchange transfusion has benefits over simple transfusion (ST), but a new meta-analysis and systematic review suggests there is insufficient evidence to say which type of exchange transfusion is superior.

Learn more

Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial

10 Jun 2022

Initial data from the first subjects to receive FTX-6058, an oral HbF inducer, showed a rapid and robust induction of HbF, and subjects achieved increases of up to 6.3% over baseline.

Learn more

Opioid Use in Vaso-Occlusive Crisis During Intravenous Opioid Drug Shortage

04 Jun 2022

Patients with sickle cell disease (SCD) are particularly vulnerable, as high amounts of IV opioid medications are standard therapy during vaso-occlusive crises (VOC). [The] institution responded to the crises by implementing IV to oral (PO) conversions of opioid therapies and encouraging multimodal pain management with non-opioid medications.

Learn more